Work

Drug companies have a duty to continue treatment

Year: 1997

Type: article

Abstract: Professor Cleaton-Jones describes the dilemma faced by South African ethics committees asked to approve clinical trials of treatments for HIV infection.We asked a member of a patient advocacy group, clinical trial coordinators, an ethicist, and a representative of a drug company to give their views

Source: BMJ

DOI: 10.1136/bmj.314.7084.889

Authors: Sean Emery, David A Cooper

Institution: UNSW Sydney

Language: English

Topic: Ethics in Clinical Research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Royal College of Surgeons of Edinburgh